Alpha Cognition Inc. (ACOGF) Research

Alpha Cognition Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering treatments for severe neurological conditions, including Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Its developmental pipeline features ALPHA-1062, an acetylcholine esterase inhibitor designed to address dementia of the Alzheimer's type and mild traumatic brain injury. The company is also advancing ALPHA-0602, a gene therapy candidate specifically for ALS. Founded in 2000, the company initially operated as Crystal Bridge Enterprises Inc. before officially changing its name to Alpha Cognition Inc. in March 2021. The corporate headquarters are located in Vancouver, Canada.

Market snapshot

Symbol
ACOGF
Price
$5.73
Market cap
$35.7M
P/E ratio
-39.22x
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$18.00

Peer companies

  • Small Pharma Inc. (DMTTF)
  • Enzo Biochem, Inc. (ENZB)
  • IntelGenx Technologies Corp. (IGXT)
  • ImmuPharma plc (IMMPF)
  • Kadimastem Ltd (KMSTF)
  • LakeShore Biopharma Co., Ltd (LSBCF)
  • Abliva AB (publ) (NEVPF)
  • Organicell Regenerative Medicine, Inc. (OCEL)

Open Alpha Cognition Inc. (ACOGF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.